| AURINIA-MERGER-SUB-INC |
AURINIA-MERGER-SUB-INC |
90%
|
Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss… |
| AURINIA-PHARMACEUTICALS-INC |
AURINIA-PHARMACEUTICALS-INC |
90%
|
Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss… |
| AURINIA-PHARMA-U-S-INC |
AURINIA-PHARMA-U-S-INC |
90%
|
Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss… |
| BROADRIDGE-CORPORATE-ISSUER-SOLUTIONS-LLC |
BROADRIDGE-CORPORATE-ISSUER-SOLUTIONS-LLC |
90%
|
Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss… |
| ENODIA-THERAPEUTICS-SAS |
ENODIA-THERAPEUTICS-SAS |
90%
|
If Parent receives proceeds in respect of the existing Asset Purchase Agreement, dated March 6, 2026, by and between the Company and Enodia Therapeutics SAS |
| EVEREST-MEDICINES-II-HK-LIMITED |
EVEREST-MEDICINES-II-HK-LIMITED |
90%
|
If Parent receives proceeds in respect of the existing Collaboration and License Agreement, dated September 20, 2023, by and between the Company and Everest Medicines II (HK) Limited |
| FORTIS-ADVISORS-LLC |
FORTIS-ADVISORS-LLC |
90%
|
Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss… |